Skip to main content

Table 1 Patients’ characteristics

From: Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients

 

N

%

Total extracellular DNA ng/mL median

p-value

Extracellular nuclear DNA ge/mL median

p-value

Extracellular mitochondrial DNA ge/mL median

p-value

All patients

67

100.0

8.3

 

2266

 

16,526

NA

Surgical Debulking

 Optimal

35

52.2

8.26

0.35

1944

0.13

11,422

0.09

 Suboptimal

32

47.8

8.94

 

2584

 

20,297

 

Histology

 Serous

53

79.1

9

0.31

2422

0.63

16,526

0.70

 Other

14

20.9

6.16

 

1919

 

13,117

 

Grade

 1 and 2

14

20.9

7.63

0.47

2083

0.49

16,470

0.90

 3

41

61.2

8.32

 

2266

 

15,646

 

 Unknown

12

17.9

      

Stage

 1

12

17.9

5.3

0.58

1862

0.45

8604

0.16

 2

7

10.4

8.26

 

2422

 

16,526

 

 3

43

64.2

9

 

2455

 

17,575

 

 4

5

7.5

9.7

 

1736

 

16,413

 

Stage

 1

12

17.9

5.3

0.19

1862

0.18

8604

0.03

 2 to 4

55

82.1

9

 

2438

 

16,984

 
  

0.0

      

Chemotherapy

 paclitaxel+carboplatin

25

37.3

6.26

0.21

1893

0.19

14,314

0.76

 paclitaxel+carboplatin+bevacizumab

42

62.7

9.17

 

2447

 

16,755

Â